The delta variant of COVID-19 has put the US in the precarious position of a fourth wave of the disease -- how efficacious are our vaccines against this variant? Also, are any new treatments for early COVID-19 being studied to help continue the fight? Find out more in this episode!
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964
References and resources:
Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 Jul 22;385(4):320-329. doi: 10.1056/NEJMoa2107058. Epub 2021 Jun 30. PMID: 34192428; PMCID: PMC8262622.
Rossignol J, Matthew C, Oaks J, et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441
Continuing Education Information:
1. Discuss the differences in effectiveness between the mRNA and adenovirus vaccines for the delta variant of COVID-19
2. Describe the use of nitazoxanide in mild to moderate COVID-19 and barriers to its use
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-XXX-H01-P
Initial release date: 8/31/21
Expiration date: 8/24/22
Complete CPE & CME details can be found here.